Blockbuster Drugs Market, 2021-2030: Focus on Product Landscape Assessment, Ongoing Clinical Trials, Promotional Content Analysis, Other Life Cycle Management Strategies, Competition from Biosimilars, Annual Treatment Cost Comparison, Sales Evolution and Future Opportunity
The blockbuster drugs market is expected to reach USD 75 billion in 2020 anticipated to grow at an exponential CAGR during the forecast period 2023-2035.
The pursuit of more refined pharmacological treatments, prompted by concerns over off-target toxicity and low specificity linked to chemical compounds, has driven the exploration for advanced interventions. The emergence of biologics, notably humanized insulin in 1982, stands as a transformative milestone that reshaped the healthcare landscape. Distinguished by their precise targeting, heightened therapeutic effectiveness, and improved safety profiles in contrast to traditional chemical drugs, biologics have revolutionized disease management. These agents possess the capacity to reach previously inaccessible biological targets, addressing conditions that were once considered untreatable. The biologics sector currently stands as the fastest-growing segment in the global pharmaceutical industry, with over 430 approved biological interventions for various disease indications in the US and Europe by September 2020. The demand for biologics remains substantial across diverse disease categories due to their myriad advantages. Antibodies, in particular, have emerged as a pivotal cornerstone in therapeutic progress, demonstrating significant success over the past two decades. The future holds immense promise for biologics, with ongoing innovations such as antibody drug conjugates, immunotherapies, bispecific antibodies, combination therapies, and cell and gene therapies. These advancements are anticipated to bring significant disruptions by expanding therapeutic targets and propelling personalized healthcare to unprecedented heights.
Despite the intricate and costly manufacturing processes involved, biopharmaceuticals, once approved, prove to be highly lucrative assets. Several biological interventions have achieved blockbuster status, yielding substantial revenues. Notable examples such as Humira®, Keytruda®, and others have consistently generated annual revenues exceeding USD 4 billion. Even post-patent expirations, original product sales often remain resilient. For instance, despite multiple approved biosimilar versions of Abbvie's Humira®, the company continues to report annual global revenues of around USD 19 billion from this drug alone. While patents for other top-selling biologic drugs are nearing expiration, creating opportunities for follow-on biologics, innovators have devised strategies to extend marketing exclusivity. These strategies involve securing authorization in new geographical regions, demonstrating therapeutic benefits for different indications, developing new formulations, showcasing combinational advantages, or introducing novel drug delivery systems. Companies behind blockbuster biologic products are poised to continue reaping the benefits of their high-value assets in the short to medium term. However, market growth for these products is projected to plateau and eventually decline as patent expirations, including extended ones, open doors for biosimilars.
Report Coverage
The pursuit of more refined pharmacological treatments, prompted by concerns over off-target toxicity and low specificity linked to chemical compounds, has driven the exploration for advanced interventions. The emergence of biologics, notably humanized insulin in 1982, stands as a transformative milestone that reshaped the healthcare landscape. Distinguished by their precise targeting, heightened therapeutic effectiveness, and improved safety profiles in contrast to traditional chemical drugs, biologics have revolutionized disease management. These agents possess the capacity to reach previously inaccessible biological targets, addressing conditions that were once considered untreatable. The biologics sector currently stands as the fastest-growing segment in the global pharmaceutical industry, with over 430 approved biological interventions for various disease indications in the US and Europe by September 2020. The demand for biologics remains substantial across diverse disease categories due to their myriad advantages. Antibodies, in particular, have emerged as a pivotal cornerstone in therapeutic progress, demonstrating significant success over the past two decades. The future holds immense promise for biologics, with ongoing innovations such as antibody drug conjugates, immunotherapies, bispecific antibodies, combination therapies, and cell and gene therapies. These advancements are anticipated to bring significant disruptions by expanding therapeutic targets and propelling personalized healthcare to unprecedented heights.
Despite the intricate and costly manufacturing processes involved, biopharmaceuticals, once approved, prove to be highly lucrative assets. Several biological interventions have achieved blockbuster status, yielding substantial revenues. Notable examples such as Humira®, Keytruda®, and others have consistently generated annual revenues exceeding USD 4 billion. Even post-patent expirations, original product sales often remain resilient. For instance, despite multiple approved biosimilar versions of Abbvie's Humira®, the company continues to report annual global revenues of around USD 19 billion from this drug alone. While patents for other top-selling biologic drugs are nearing expiration, creating opportunities for follow-on biologics, innovators have devised strategies to extend marketing exclusivity. These strategies involve securing authorization in new geographical regions, demonstrating therapeutic benefits for different indications, developing new formulations, showcasing combinational advantages, or introducing novel drug delivery systems. Companies behind blockbuster biologic products are poised to continue reaping the benefits of their high-value assets in the short to medium term. However, market growth for these products is projected to plateau and eventually decline as patent expirations, including extended ones, open doors for biosimilars.
Report Coverage
- The report conducts an analysis of the healthcare digital marketing market focusing on biologics types and key industry players.
- It evaluates the factors influencing market growth, such as drivers, restraints, opportunities, and challenges.
- The report provides insights into the potential advantages and barriers within the market, offering information on the competitive landscape for leading players.
- A comprehensive evaluation is presented regarding the current market scenario for prominent biologics. This includes details on developers (year of establishment, company size, headquarters location, and current portfolio of top-selling biologics), encompassing biologic types, administration routes, target genes/antigens, packaging formats, disease indications, and therapeutic areas.
- An in-depth review is conducted focusing on key therapeutic areas within companies developing top-selling biologics, including oncology, metabolic disorders, autoimmune diseases, gastrointestinal disorders, ophthalmic conditions, CNS/neurological disorders, cardiovascular diseases, blood disorders, respiratory illnesses, bone disorders, and others.
- Detailed analysis is provided on the revenues generated by 60+ top-selling biologics from 2016 to 2020. This includes reasons for significant sales fluctuations during this period, specifically addressing revenue specifics for 2020 based on biologic type and developer.
- The report analyzes completed, ongoing, and planned clinical studies for top-selling biologics, emphasizing trials assessing approved biologics for potential combinations, device assessments, and comparisons. Parameters covered include trial registration year, recruitment status, patient population, study design, therapeutic area, trial locations, and leading organizations.
- A comprehensive exploration is conducted into the promotional strategies employed by top-selling biologic developers, utilizing a Harvey ball analysis to illustrate the extent of promotional content on product websites. Profiles of the top 7 blockbuster biologics feature their promotional content, patient support programs, and a section on direct-to-consumer (DTC) advertisements.
- The report offers a concise examination of product lifecycle management strategies implemented by stakeholders from 2016 to 2020. This includes geographical expansion, additional disease indications, reformulations, combination therapies, alternate administration routes, reimbursement programs, and pricing strategies, specifically focusing on the top 10 biologics in terms of revenues.
- A detailed breakdown is provided on the annual treatment costs for over 60 top-selling biologics, represented in grids based on biologic type.
- Gentech / Roche
- AbbVie
- Janssen Biotech
- Merck
- Amgen
- Eli Lilly
- Sanofi
- Bristol Myers Squibb
- Novo Nordisk
- Alexion Pharmaceuticals
- AstraZeneca
- Biogen
- UCB
- GlaxoSmithKline:
- Biomarin
- Bayer
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Therapeutic Molecules
3.3. Biologics
3.3.1. Type of Biologics
3.3.1.1. Peptides
3.3.1.2. Monoclonal Antibodies
3.3.1.3. Gene Therapies
3.3.1.4. Growth Factors
3.3.1.5. Hormones
3.3.1.6. Enzymes
3.3.1.7. Vaccines
3.3.1.8. Blood and Related Products
3.3.2. Regulatory Considerations
3.3. Competition from Biosimilars
3.4. Key Market Drivers and Associated Trends
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Top Selling Biologics: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Number of Top Selling Biologics
4.3. Top Selling Biologics: Market Landscape
4.3.1. Analysis by Type of Biologic
4.3.2. Analysis by Route of Administration
4.3.3. Analysis by Target Antigen / Gene
4.3.4. Analysis by Type of Biologic and Route of Administration
4.3.5. Analysis by Type of Biologic and Target Antigen / Gene
4.4. Information on Dose Strength and Type of Packaging
4.5. Top Selling Biologics: Key Disease Indications
4.5.1. Analysis by Key Indications
4.6.1 Top Selling Biologics: Target Therapeutic Areas
4.6.2. Analysis by Type of Oncological Disorder
4.6.3. Analysis by Type of Metabolic Disorder
4.6.3.1. Analysis by Type of Autoimmune Disorder
4.6.3.2. Analysis by Type of Gastrointestinal Disorder
4.6.3.3. Analysis by Type of Ophthalmic Disorder
4.6.3.4. Analysis by Type of CNS / Neurological Disorder
4.6.3.5. Analysis by Type of Cardiovascular Disorder
4.6.3.6. Analysis by Type of Blood Disorder
4.6.3.7. Analysis by Type of Respiratory Disorder
4.6.3.8. Analysis by Type of Bone Disorder
5. GLOBAL SALES ANALYSIS OF TOP SELLING BIOLOGICS
5.1. Chapter Overview
5.2. Top Selling Biologics: Global Sales (2020)
5.2.1. Analysis of Global Sales by Type of Biologic
5.2.2. Analysis of Global Sales by Developer
5.2.3. Genentech / Roche: Portfolio of Top Selling Biologics
5.2.3.1. Genentech / Roche: Historical sales of Top Selling Enzymes
5.2.3.2. Genentech / Roche: Historical sales of Top Selling Monoclonal Antibodies
5.2.3.3. Genentech / Roche: Historical sales of Top Selling Hormones
5.2.3.4. Genentech / Roche: Historical sales of Top Selling Other Biologics
5.2.4. AbbVie: Portfolio of Top Selling Biologics
5.2.4.1. AbbVie: Historical sales of Top Selling Monoclonal Antibodies
5.2.4.2. AbbVie: Historical sales of Top Selling Fusion Proteins
5.2.5. Janssen Biotech / Johnson & Johnson: Portfolio of Top Selling Biologics
5.2.5.1. Janssen Biotech / Johnson & Johnson: Historical sales of Top Selling Monoclonal Antibodies
5.2.5.2. Janssen Biotech / Johnson & Johnson: Historical sales of Top Selling Hormones
5.2.6. Merck: Portfolio of Top Selling Biologics
5.2.6.1. Merck: Historical sales of Top Selling Hormones
5.2.6.2. Merck: Historical sales of Top Selling Monoclonal Antibodies
5.2.6.3. Merck: Historical sales of Top Selling Vaccines
5.2.7. Amgen: Portfolio of Top Selling Biologics
5.2.7.1. Amgen: Historical sales of Top Selling Monoclonal Antibodies
5.2.7.2. Amgen: Historical sales of Top Selling Hormones
5.2.7.3. Amgen: Historical sales of Top Selling Hormones
5.2.8. Eli Lilly: Portfolio of Top Selling Biologics
5.2.8.1. Eli Lilly: Historical sales of Top Selling Monoclonal Antibodies
5.2.8.2. Eli Lilly: Historical sales of Top Selling Hormones
5.2.8.3. Eli Lilly: Historical sales of Top Selling Fusion Proteins
5.2.9. Sanofi: Portfolio of Top Selling Biologics
5.2.9.1. Sanofi: Historical sales of Top Selling Monoclonal Antibodies
5.2.9.2. Sanofi: Historical sales of Top Selling Enzymes
5.2.9.3. Sanofi: Historical sales of Top Selling Hormones
5.2.10. Bristol Myers Squibb: Portfolio of Top Selling Biologics
5.2.10.1. Bristol Myers Squibb: Historical sales of Top Selling Monoclonal Antibodies
5.2.10.2. Bristol Myers Squibb: Historical sales of Top Selling Fusion Proteins
5.2.11. Novo Nordisk: Portfolio of Top Selling Biologics
5.2.11.1. Novo Nordisk: Historical sales of Top Selling Hormones
5.2.12. Novartis: Portfolio of Top Selling Biologics
5.2.12.1. Novartis: Historical sales of Top Selling Monoclonal Antibodies
5.2.13. Alexion Pharmaceuticals: Portfolio of Top Selling Biologics
5.2.13.1. Alexion Pharmaceuticals: Historical sales of Top Selling Monoclonal Antibodies
5.2.13.2. Alexion Pharmaceuticals: Historical sales of Top Selling Enzymes
5.2.14. AstraZeneca: Portfolio of Top Selling Biologics
5.2.14.1. AstraZeneca: Historical sales of Top Selling Monoclonal Antibodies
5.2.15. Biogen: Portfolio of Top Selling Biologics
5.2.15.1. Biogen: Historical sales of Top Selling Monoclonal Antibodies
5.2.15.2. Biogen: Historical sales of Top Selling Gene Therapy
5.2.16. UCB: Portfolio of Top Selling Biologics
5.2.16.1. UCB: Historical sales of Top Selling Monoclonal Antibodies
5.2.17. GlaxoSmithKline: Portfolio of Top Selling Biologics
5.2.17.1. GlaxoSmithKline: Historical sales of Top Selling Monoclonal Antibodies
5.2.18. Biomarin: Portfolio of Top Selling Biologics
5.2.18.1. Biomarin: Historical sales of Top Selling Enzymes
5.2.19. Bayer: Portfolio of Top Selling Biologics
5.2.19.1. Bayer: Historical sales of Top Selling Interferons
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Top Selling Biologics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Recruitment Status
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Patient Segment
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Leading Organizations: Analysis by Number of Registered Trials
6.3.8. Analysis by Target Therapeutic Area
6.3.9. Analysis by Key Biologics
7. PROMOTIONAL ANALYSIS
7.1. Context and Background
7.2. Top Selling Biologics: Product Website Analysis
7.3. Top Selling Biologics: Patient Support-related Services Provided for Top Selling Biologics
7.4. Humira®: Promotional Analysis
7.4.1. Product Website Analysis
7.4.1.1. Messages for Healthcare Professionals
7.4.1.2. Messages for Patients
7.4.1.3. Informative Downloads
7.4.2. Patient Support Services
7.4.3. Advertisements
7.5. Keytruda®: Promotional Analysis
7.5.1. Product Website Analysis
7.5.1.1. Messages for Healthcare Professionals
7.5.1.2. Messages for Patients
7.5.1.3. Informative Downloads
7.5.2. Patient Support Services
7.5.3. Advertisements
7.6. Opdivo®: Promotional Analysis
7.6.1. Product Website Analysis
7.6.1.1. Messages for Healthcare Professionals
7.6.1.2. Messages for Patients
7.6.1.3. Informative Downloads
7.6.2. Patient Support Services
7.6.3. Advertisements
7.7. Avastin®: Promotional Analysis
7.7.1. Product Website Analysis
7.7.1.1. Messages for Healthcare Professionals
7.7.1.2. Messages for Patients
7.7.1.3. Informative Downloads
7.7.2. Patient Support Services
7.8. Rituxan®: Promotional Analysis
7.8.1. Product Website Analysis
7.8.1.1. Messages for Healthcare Professionals
7.8.1.2. Messages for Patients
7.8.1.3. Informative Downloads
7.8.2. Patient Support Services
7.9. Stelara®: Promotional Analysis
7.9.1. Product Website Analysis
7.9.1.1. Messages for Healthcare Professionals
7.9.1.2. Messages for Patients
7.9.1.3. Informative Downloads
7.9.2. Patient Support Services
7.9.3 Advertisements
7.10. Herceptin: Promotional Analysis
7.10.1. Product Website Analysis
7.10.1.1. Messages for Healthcare Professionals
7.10.1.2. Messages for Patients
7.10.1.3. Informative Downloads
7.10.2. Patient Support Services
7.11. Enbrel: Promotional Analysis
7.11.1. Product Website Analysis
7.11.1.1. Messages for Healthcare Professionals
7.11.1.2. Messages for Patients
7.11.1.3. Informative Downloads
7.11.2. Patient Support Services
7.11.3. Advertisements
8. PRODUCT LIFECYCLE MANAGEMENT STRATEGIES
8.1. Introduction
8.2. Key LCM Strategies
8.2.1. Geographical Expansion
8.2.2. Approval for Additional Disease Indications
8.2.3. Reformulations
8.2.4. Combination Therapies
8.2.5. Exploiting Alternate Routes of Administration
8.2.6. Reimbursement Programs
8.2.6.1. Humira®
8.2.6.2. Keytruda®
8.2.6.3. Opdivo®
8.2.6.4. Avastin®
8.2.6.5. Rituxan®
8.2.6.6. Stelara®
8.2.6.7. Herceptin®
8.2.6.8. Enbrel®
8.2.6.9 Remicade®
8.2.6.10 Trulicity®
8.2.7. Pricing Strategies
8.2.7.1. Humira®
8.2.7.2. Keytruda®
8.2.7.3. Opdivo®
8.2.7.4. Avastin®
8.3. Concluding Remarks
9. COST PRICE ANALYSIS
9.1. Chapter Overview
9.2. Factors Contributing to the Price of Biologics
9.3. Annual Treatment Cost of Top Selling Biologics
9.3.1. Price Comparison across Target Therapeutic Areas
9.3.1.1. Oncological Disorders
9.3.1.2. Metabolic Disorders
9.3.1.3. Autoimmune Disorders
9.3.1.4. Gastrointestinal Disorders
9.3.1.5. Ophthalmic Disorders
9.3.1.6. CNS / Neurological Disorders
9.3.1.7. Cardiovascular Disorders
9.3.1.8. Blood Disorders
9.3.1.9. Respiratory Disorders
9.3.1.10. Bone Disorders
9.4 Concluding Remarks
10. BIOSIMILARS
10.1. Chapter Overview
10.2. Introduction to Biosimilars
10.3. Need For Biosimilars
10.4. Biosimilars of Top Selling Biologics
10.4.1. Analysis by Highest Phase of Development
10.4.2. Analysis by Geography
10.4.3. Biosimilar of Top Selling Biologics: Developers Landscape
10.4.3.1. Analysis by Distribution Network
10.4.3.2. Analysis by Location of Headquarters
10.5. Biosimilars VS Top Selling Biologics
10.5.1. Manufacturing
1.5.2. Clinical Trials
10.2.3. Marketing
10.5.4. Safety
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Scope and Limitations
11.3. Key Assumptions and Forecast Methodology
11.4. Global Top Selling Biologics Market, 2021-2030
11.4.1. Top Selling Biologics Market: Distribution by Type of Biologic, 2021-2030
11.4.2. Top Selling Biologics Market: Distribution by Key Players, 2021-2030
11.5. Top Selling Biologics Market: Product-wise Sales Forecast
11.3. Top Selling Biologics: Product Wise Forecast
11.3.1. Monoclonal Antibodies
11.3.1.1. Actemra®
11.3.1.2. Avastin®
11.3.1.3. Benlysta®
11.3.1.4. Cosentyx®
11.3.1.5. Cyramza®
11.3.1.6. Darzalex®
11.3.1.7. Dupixent®
11.3.1.8. Erbitux®
11.3.1.9. Fasenra®
11.3.1.10. Gazyva®
11.3.1.11. Hemlibra®
11.3.1.12. Herceptin®
11.3.1.13. Humira®
11.3.1.14. Ilaris®
11.3.1.15. Imfinzi®
11.3.1.16. Keytruda®
11.3.1.17. Lucentis®
11.3.1.18. Nucala®
11.3.1.19. Ocrevus™
11.3.1.20. Opdivo®
11.3.1.21. Perjeta®
11.3.1.22. Prolia®
11.3.1.23. Remicade®
11.3.1.24. Repatha®
11.3.1.25. Rituxan®
11.3.1.26. Soliris®
11.3.1.27. Stelara®
11.3.1.28. Synagis®
11.3.1.29. Taltz®
11.3.1.30. Tecentriq®
11.3.1.31. Tremfya®
11.3.1.32. Tysabri®
11.3.1.33. Vectibix®
11.3.1.34. Xgeva®
11.3.1.35. Xolair®
11.3.1.36. Yervoy®
11.3.2. Hormones
11.3.2.1. Forteo®
11.3.2.2. Gonal-f®
11.3.2.3. Humalog®
11.3.2.4. Humulin®
11.3.2.5. Lantus®
11.3.2.6. Levemir®
11.3.2.7. Mircera®
11.3.2.8. Neulasta®
11.3.2.9. Novolog®
11.3.2.10. Procrit / Eprex®
11.3.2.11. Toujeo®
11.3.2.12. Tresiba®
11.3.2.13. Victoza®
11.3.3. Enzymes
11.3.3.1. Activase®
11.3.3.2. Fabrazyme®
11.3.3.3. Myozyme®
11.3.3.4. Pulmozyme®
11.3.3.5. Strensiq®
11.3.3.6. Vimizim®
11.3.4. Fusion Proteins
11.3.4.1. Aranesp®
11.3.4.2. Botox®
11.3.4.3. Enbrel®
11.3.4.4. Epogen®
11.3.4.5. Orencia®
11.3.4.6. Trulicity®
11.3.5. Interferons
11.3.5.1. Avonex / Rebif®
11.3.5.2. Betaseron®
11.3.5.3. Kadcyla®
11.3.6. Gene therapies
11.3.6.1. Spinraza®
11.3.7. Antibody fragments
11.3.7.1. Cimzia®
11.3.8. Vaccines
11.3.8.1. Varivax®
12. CONCLUSION
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Therapeutic Molecules
3.3. Biologics
3.3.1. Type of Biologics
3.3.1.1. Peptides
3.3.1.2. Monoclonal Antibodies
3.3.1.3. Gene Therapies
3.3.1.4. Growth Factors
3.3.1.5. Hormones
3.3.1.6. Enzymes
3.3.1.7. Vaccines
3.3.1.8. Blood and Related Products
3.3.2. Regulatory Considerations
3.3. Competition from Biosimilars
3.4. Key Market Drivers and Associated Trends
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Top Selling Biologics: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Number of Top Selling Biologics
4.3. Top Selling Biologics: Market Landscape
4.3.1. Analysis by Type of Biologic
4.3.2. Analysis by Route of Administration
4.3.3. Analysis by Target Antigen / Gene
4.3.4. Analysis by Type of Biologic and Route of Administration
4.3.5. Analysis by Type of Biologic and Target Antigen / Gene
4.4. Information on Dose Strength and Type of Packaging
4.5. Top Selling Biologics: Key Disease Indications
4.5.1. Analysis by Key Indications
4.6.1 Top Selling Biologics: Target Therapeutic Areas
4.6.2. Analysis by Type of Oncological Disorder
4.6.3. Analysis by Type of Metabolic Disorder
4.6.3.1. Analysis by Type of Autoimmune Disorder
4.6.3.2. Analysis by Type of Gastrointestinal Disorder
4.6.3.3. Analysis by Type of Ophthalmic Disorder
4.6.3.4. Analysis by Type of CNS / Neurological Disorder
4.6.3.5. Analysis by Type of Cardiovascular Disorder
4.6.3.6. Analysis by Type of Blood Disorder
4.6.3.7. Analysis by Type of Respiratory Disorder
4.6.3.8. Analysis by Type of Bone Disorder
5. GLOBAL SALES ANALYSIS OF TOP SELLING BIOLOGICS
5.1. Chapter Overview
5.2. Top Selling Biologics: Global Sales (2020)
5.2.1. Analysis of Global Sales by Type of Biologic
5.2.2. Analysis of Global Sales by Developer
5.2.3. Genentech / Roche: Portfolio of Top Selling Biologics
5.2.3.1. Genentech / Roche: Historical sales of Top Selling Enzymes
5.2.3.2. Genentech / Roche: Historical sales of Top Selling Monoclonal Antibodies
5.2.3.3. Genentech / Roche: Historical sales of Top Selling Hormones
5.2.3.4. Genentech / Roche: Historical sales of Top Selling Other Biologics
5.2.4. AbbVie: Portfolio of Top Selling Biologics
5.2.4.1. AbbVie: Historical sales of Top Selling Monoclonal Antibodies
5.2.4.2. AbbVie: Historical sales of Top Selling Fusion Proteins
5.2.5. Janssen Biotech / Johnson & Johnson: Portfolio of Top Selling Biologics
5.2.5.1. Janssen Biotech / Johnson & Johnson: Historical sales of Top Selling Monoclonal Antibodies
5.2.5.2. Janssen Biotech / Johnson & Johnson: Historical sales of Top Selling Hormones
5.2.6. Merck: Portfolio of Top Selling Biologics
5.2.6.1. Merck: Historical sales of Top Selling Hormones
5.2.6.2. Merck: Historical sales of Top Selling Monoclonal Antibodies
5.2.6.3. Merck: Historical sales of Top Selling Vaccines
5.2.7. Amgen: Portfolio of Top Selling Biologics
5.2.7.1. Amgen: Historical sales of Top Selling Monoclonal Antibodies
5.2.7.2. Amgen: Historical sales of Top Selling Hormones
5.2.7.3. Amgen: Historical sales of Top Selling Hormones
5.2.8. Eli Lilly: Portfolio of Top Selling Biologics
5.2.8.1. Eli Lilly: Historical sales of Top Selling Monoclonal Antibodies
5.2.8.2. Eli Lilly: Historical sales of Top Selling Hormones
5.2.8.3. Eli Lilly: Historical sales of Top Selling Fusion Proteins
5.2.9. Sanofi: Portfolio of Top Selling Biologics
5.2.9.1. Sanofi: Historical sales of Top Selling Monoclonal Antibodies
5.2.9.2. Sanofi: Historical sales of Top Selling Enzymes
5.2.9.3. Sanofi: Historical sales of Top Selling Hormones
5.2.10. Bristol Myers Squibb: Portfolio of Top Selling Biologics
5.2.10.1. Bristol Myers Squibb: Historical sales of Top Selling Monoclonal Antibodies
5.2.10.2. Bristol Myers Squibb: Historical sales of Top Selling Fusion Proteins
5.2.11. Novo Nordisk: Portfolio of Top Selling Biologics
5.2.11.1. Novo Nordisk: Historical sales of Top Selling Hormones
5.2.12. Novartis: Portfolio of Top Selling Biologics
5.2.12.1. Novartis: Historical sales of Top Selling Monoclonal Antibodies
5.2.13. Alexion Pharmaceuticals: Portfolio of Top Selling Biologics
5.2.13.1. Alexion Pharmaceuticals: Historical sales of Top Selling Monoclonal Antibodies
5.2.13.2. Alexion Pharmaceuticals: Historical sales of Top Selling Enzymes
5.2.14. AstraZeneca: Portfolio of Top Selling Biologics
5.2.14.1. AstraZeneca: Historical sales of Top Selling Monoclonal Antibodies
5.2.15. Biogen: Portfolio of Top Selling Biologics
5.2.15.1. Biogen: Historical sales of Top Selling Monoclonal Antibodies
5.2.15.2. Biogen: Historical sales of Top Selling Gene Therapy
5.2.16. UCB: Portfolio of Top Selling Biologics
5.2.16.1. UCB: Historical sales of Top Selling Monoclonal Antibodies
5.2.17. GlaxoSmithKline: Portfolio of Top Selling Biologics
5.2.17.1. GlaxoSmithKline: Historical sales of Top Selling Monoclonal Antibodies
5.2.18. Biomarin: Portfolio of Top Selling Biologics
5.2.18.1. Biomarin: Historical sales of Top Selling Enzymes
5.2.19. Bayer: Portfolio of Top Selling Biologics
5.2.19.1. Bayer: Historical sales of Top Selling Interferons
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Top Selling Biologics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Recruitment Status
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Patient Segment
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Leading Organizations: Analysis by Number of Registered Trials
6.3.8. Analysis by Target Therapeutic Area
6.3.9. Analysis by Key Biologics
7. PROMOTIONAL ANALYSIS
7.1. Context and Background
7.2. Top Selling Biologics: Product Website Analysis
7.3. Top Selling Biologics: Patient Support-related Services Provided for Top Selling Biologics
7.4. Humira®: Promotional Analysis
7.4.1. Product Website Analysis
7.4.1.1. Messages for Healthcare Professionals
7.4.1.2. Messages for Patients
7.4.1.3. Informative Downloads
7.4.2. Patient Support Services
7.4.3. Advertisements
7.5. Keytruda®: Promotional Analysis
7.5.1. Product Website Analysis
7.5.1.1. Messages for Healthcare Professionals
7.5.1.2. Messages for Patients
7.5.1.3. Informative Downloads
7.5.2. Patient Support Services
7.5.3. Advertisements
7.6. Opdivo®: Promotional Analysis
7.6.1. Product Website Analysis
7.6.1.1. Messages for Healthcare Professionals
7.6.1.2. Messages for Patients
7.6.1.3. Informative Downloads
7.6.2. Patient Support Services
7.6.3. Advertisements
7.7. Avastin®: Promotional Analysis
7.7.1. Product Website Analysis
7.7.1.1. Messages for Healthcare Professionals
7.7.1.2. Messages for Patients
7.7.1.3. Informative Downloads
7.7.2. Patient Support Services
7.8. Rituxan®: Promotional Analysis
7.8.1. Product Website Analysis
7.8.1.1. Messages for Healthcare Professionals
7.8.1.2. Messages for Patients
7.8.1.3. Informative Downloads
7.8.2. Patient Support Services
7.9. Stelara®: Promotional Analysis
7.9.1. Product Website Analysis
7.9.1.1. Messages for Healthcare Professionals
7.9.1.2. Messages for Patients
7.9.1.3. Informative Downloads
7.9.2. Patient Support Services
7.9.3 Advertisements
7.10. Herceptin: Promotional Analysis
7.10.1. Product Website Analysis
7.10.1.1. Messages for Healthcare Professionals
7.10.1.2. Messages for Patients
7.10.1.3. Informative Downloads
7.10.2. Patient Support Services
7.11. Enbrel: Promotional Analysis
7.11.1. Product Website Analysis
7.11.1.1. Messages for Healthcare Professionals
7.11.1.2. Messages for Patients
7.11.1.3. Informative Downloads
7.11.2. Patient Support Services
7.11.3. Advertisements
8. PRODUCT LIFECYCLE MANAGEMENT STRATEGIES
8.1. Introduction
8.2. Key LCM Strategies
8.2.1. Geographical Expansion
8.2.2. Approval for Additional Disease Indications
8.2.3. Reformulations
8.2.4. Combination Therapies
8.2.5. Exploiting Alternate Routes of Administration
8.2.6. Reimbursement Programs
8.2.6.1. Humira®
8.2.6.2. Keytruda®
8.2.6.3. Opdivo®
8.2.6.4. Avastin®
8.2.6.5. Rituxan®
8.2.6.6. Stelara®
8.2.6.7. Herceptin®
8.2.6.8. Enbrel®
8.2.6.9 Remicade®
8.2.6.10 Trulicity®
8.2.7. Pricing Strategies
8.2.7.1. Humira®
8.2.7.2. Keytruda®
8.2.7.3. Opdivo®
8.2.7.4. Avastin®
8.3. Concluding Remarks
9. COST PRICE ANALYSIS
9.1. Chapter Overview
9.2. Factors Contributing to the Price of Biologics
9.3. Annual Treatment Cost of Top Selling Biologics
9.3.1. Price Comparison across Target Therapeutic Areas
9.3.1.1. Oncological Disorders
9.3.1.2. Metabolic Disorders
9.3.1.3. Autoimmune Disorders
9.3.1.4. Gastrointestinal Disorders
9.3.1.5. Ophthalmic Disorders
9.3.1.6. CNS / Neurological Disorders
9.3.1.7. Cardiovascular Disorders
9.3.1.8. Blood Disorders
9.3.1.9. Respiratory Disorders
9.3.1.10. Bone Disorders
9.4 Concluding Remarks
10. BIOSIMILARS
10.1. Chapter Overview
10.2. Introduction to Biosimilars
10.3. Need For Biosimilars
10.4. Biosimilars of Top Selling Biologics
10.4.1. Analysis by Highest Phase of Development
10.4.2. Analysis by Geography
10.4.3. Biosimilar of Top Selling Biologics: Developers Landscape
10.4.3.1. Analysis by Distribution Network
10.4.3.2. Analysis by Location of Headquarters
10.5. Biosimilars VS Top Selling Biologics
10.5.1. Manufacturing
1.5.2. Clinical Trials
10.2.3. Marketing
10.5.4. Safety
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Scope and Limitations
11.3. Key Assumptions and Forecast Methodology
11.4. Global Top Selling Biologics Market, 2021-2030
11.4.1. Top Selling Biologics Market: Distribution by Type of Biologic, 2021-2030
11.4.2. Top Selling Biologics Market: Distribution by Key Players, 2021-2030
11.5. Top Selling Biologics Market: Product-wise Sales Forecast
11.3. Top Selling Biologics: Product Wise Forecast
11.3.1. Monoclonal Antibodies
11.3.1.1. Actemra®
11.3.1.2. Avastin®
11.3.1.3. Benlysta®
11.3.1.4. Cosentyx®
11.3.1.5. Cyramza®
11.3.1.6. Darzalex®
11.3.1.7. Dupixent®
11.3.1.8. Erbitux®
11.3.1.9. Fasenra®
11.3.1.10. Gazyva®
11.3.1.11. Hemlibra®
11.3.1.12. Herceptin®
11.3.1.13. Humira®
11.3.1.14. Ilaris®
11.3.1.15. Imfinzi®
11.3.1.16. Keytruda®
11.3.1.17. Lucentis®
11.3.1.18. Nucala®
11.3.1.19. Ocrevus™
11.3.1.20. Opdivo®
11.3.1.21. Perjeta®
11.3.1.22. Prolia®
11.3.1.23. Remicade®
11.3.1.24. Repatha®
11.3.1.25. Rituxan®
11.3.1.26. Soliris®
11.3.1.27. Stelara®
11.3.1.28. Synagis®
11.3.1.29. Taltz®
11.3.1.30. Tecentriq®
11.3.1.31. Tremfya®
11.3.1.32. Tysabri®
11.3.1.33. Vectibix®
11.3.1.34. Xgeva®
11.3.1.35. Xolair®
11.3.1.36. Yervoy®
11.3.2. Hormones
11.3.2.1. Forteo®
11.3.2.2. Gonal-f®
11.3.2.3. Humalog®
11.3.2.4. Humulin®
11.3.2.5. Lantus®
11.3.2.6. Levemir®
11.3.2.7. Mircera®
11.3.2.8. Neulasta®
11.3.2.9. Novolog®
11.3.2.10. Procrit / Eprex®
11.3.2.11. Toujeo®
11.3.2.12. Tresiba®
11.3.2.13. Victoza®
11.3.3. Enzymes
11.3.3.1. Activase®
11.3.3.2. Fabrazyme®
11.3.3.3. Myozyme®
11.3.3.4. Pulmozyme®
11.3.3.5. Strensiq®
11.3.3.6. Vimizim®
11.3.4. Fusion Proteins
11.3.4.1. Aranesp®
11.3.4.2. Botox®
11.3.4.3. Enbrel®
11.3.4.4. Epogen®
11.3.4.5. Orencia®
11.3.4.6. Trulicity®
11.3.5. Interferons
11.3.5.1. Avonex / Rebif®
11.3.5.2. Betaseron®
11.3.5.3. Kadcyla®
11.3.6. Gene therapies
11.3.6.1. Spinraza®
11.3.7. Antibody fragments
11.3.7.1. Cimzia®
11.3.8. Vaccines
11.3.8.1. Varivax®
12. CONCLUSION
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
